Adding Chemotherapy in Medulloblastoma Linked With Improved Survival

Video

A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation for adults with medulloblastoma improves survival.

A recent retrospective study found that adding chemotherapy to postoperative treatment of craniospinal radiation improves survival in adult medulloblastoma patients.

The study examined 751 patients from the National Cancer Data Base: 520 received both chemotherapy and radiation therapy following surgery, and 231 received only radiation therapy. Estimated overall survival at 5 years was 86.1% in patients who received chemotherapy compared with 71.6% in patients who received radiation alone. One of the study limitations was the lack of information on tumor mutation status.

In this video Benjamin Kann, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses the results.

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Related Content